Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | Director | May 19, 2026 | May 21, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2036-05-18 | Direct | 50,000 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Vericel Corp
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,300 |
Ending reported balance
After 2026-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 7,000 · Balance 25,300 Row 2 · 2026-08-12 · Sale · Disposed 7,000 · Balance 18,300 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2028-05-02 | Direct | 7,000 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Acquired 7,000 · Balance 7,000 F2: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
F2: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 10,681 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 2,663 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 11,262 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 20,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 24,334 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 18,806 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Decibel Therapeutics, Inc.
Report date September 25, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 1
1 source rowRow 1 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 5,000 unvested Company RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2032-10-09 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),
F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.
F3: Includes 5,000 unvested Company RSUs.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-26-033143 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $44.53 | $311,710.00 |
DisclosureSEC source: 0001140361-26-033143 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,300 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $13.05 | $91,350.00 |
DisclosureSEC source: 0001140361-26-033143 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:49 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-234665 · ownership.xml · derivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · derivative · entry 6 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 3,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · derivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,500 | $32.82 | $114,870.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · nonDerivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,300 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,500 | $13.05 | $45,675.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,500 | $32.83 | $114,905.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,300 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,500 | $2.63 | $9,205.00 |
DisclosureSEC source: 0001140361-26-021656 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018544 · form4.xml · derivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001140361-26-018544 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-04-29 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018544 · form4.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-018544 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001140361-26-005417 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 7,000 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $34.66 | $242,620.00 |
DisclosureSEC source: 0001140361-26-005417 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,100 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $2.63 | $18,410.00 |
DisclosureSEC source: 0001140361-26-005417 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:22 UTC | Invivyd, Inc. IVVD · Entity 721 | PurchaseCommon Stock | 50,000 | $2.50 | $125,000.00 |
DisclosureSEC source: 0001193125-25-289825 · ownership.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents shares of common stock acquired in an underwritten public offering. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001140361-25-041647 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 7,000 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $38.59 | $270,130.00 |
DisclosureSEC source: 0001140361-25-041647 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,100 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $2.63 | $18,410.00 |
DisclosureSEC source: 0001140361-25-041647 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001140361-25-029856 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $35.92 | $251,440.00 |
DisclosureSEC source: 0001140361-25-029856 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,100 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $2.76 | $19,320.00 |
DisclosureSEC source: 0001140361-25-029856 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:14 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000950170-25-076332 · ownership.xml · derivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-19 F1 · derivative.exercise_date: This option was granted on May 20, 2025 and vests in full upon the earlier of (i) May 20, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001140361-25-018156 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $39.98 | $279,860.00 |
DisclosureSEC source: 0001140361-25-018156 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,100 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $2.76 | $19,320.00 |
DisclosureSEC source: 0001140361-25-018156 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017117 · form4.xml · derivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $38.02 | $0.00 |
DisclosureSEC source: 0001140361-25-017117 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2035-04-30 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017117 · form4.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-017117 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 1, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · derivative · entry 6 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · derivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,000 | $55.43 | $55,430.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · nonDerivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,900 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,000 | $2.76 | $2,760.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 6,000 | $55.47 | $332,820.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,900 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,000 | $3.74 | $22,440.00 |
DisclosureSEC source: 0001140361-25-004765 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-047070 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 7,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,000 | $55.54 | $388,780.00 |
DisclosureSEC source: 0001140361-24-047070 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,900 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,000 | $3.74 | $26,180.00 |
DisclosureSEC source: 0001140361-24-047070 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · derivative · entry 6 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F4 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · derivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_date: These options, representing the right to purchase 5,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,000 | $45.99 | $91,980.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · nonDerivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,900 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,000 | $3.74 | $7,480.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $45.92 | $229,600.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,900 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001140361-24-036617 · form4.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 23, 2024 22:26 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0000950170-24-064138 · ownership.xml · derivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2024 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024330 · form4.xml · derivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $47.08 | $0.00 |
DisclosureSEC source: 0001140361-24-024330 · form4.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2034-05-01 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.